The Wuhan institute for cell and gene therapy. [Photo/WeChat account: whkfq]
Wuhan Economic & Technological Development Zone (WEDZ)'s biopharmaceutical innovation park has commenced operations, marking a significant milestone in the region's biopharmaceutical industry development.
Key projects, including the Wuhan institute for cell and gene therapy, have established their presence in the park.
The institute focuses on both viral and non-viral vector technologies, creating a platform for research and pilot production of cell and gene therapy (CGT) drugs.
The park integrates a range of functions, including R&D incubation, pilot production, and commercial facilities, to foster innovation and collaboration in the industry.
Authorities are committed to attracting leading enterprises, consolidating resources across the supply chain, and accelerating the commercialization of innovative achievements.
